

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031.
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Sheet	1	of	3	Application Number	-----
				Filing Date	November 7, 2001
				First Named Inventor	Michael N. Gould
				Group Art Unit	1614
				Examiner Name	D. Jones
				Attorney Docket Number	960296.97711

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
D	1.	RAJESH, D. et al., Perillyl Alcohol as a Radiosensitizer in Malignant Gliomas, abstract of presentation made at SNO Meeting (11/12/2000), Chicago.	
D	4.	BOESEN-DE COCK, JEANINE G.R., et. al., Common Regulation of Apoptosis Signaling Induced by CD95 and the DNA-damaging Stimuli Etoposide and -Radiation Downstream from Caspase-8 Activation, Journal of Bio. Chem., 274:20, Issue of May 14, 14255-14261, 1999.	
	5.	DUAN, LIAN et al., Sensitization of Human Malignant Glioma Cell Lines to Tumor Necrosis Factor-Induced Apoptosis by Cisplatin, Journal of Neuro-Oncology 52:23-36, 2001.	
	6.	FULDA, SIMONE et al., The CD95 (APO-1/Fas) System Mediates Drug-Induced Apoptosis in Neuroblastoma Cells, Cancer Research 57, 3823-3829, Sept. 1, 1997.	
	7.	FULDA, SIMONE et al., Activation of the CD95 (APO-1/Fas) Pathway in Drug- and -Irradiation-induced Apoptosis of Brain Tumor Cells, Cell Death and Differentiation (1998) 5, 884-893.	
	8.	GREEN, DOUGLAS R., Apoptotic Pathways: The Roads to Ruin, Cell 94:695-698, Sept. 18, 1998.	
	9.	HERR, INGRID et al., Activation of CD95 (APO-1/Fas) Signaling by Ceramide Mediates Cancer Therapy-Induced Apoptosis, EMBO Journal 16:20, 6200-6208, 1997.	
	10.	HOUGHTON, JANET A. et al., The Fas Signaling Pathway is Functional in Colon Carcinoma Cells and Induces Apoptosis, Clin. Cancer Res. 3:2205-2209, Dec. 1997.	
D	11.	KIMURA, KOTOHIKO et al., Tumor Necrosis Factor- and Fas Activate Complementary Fas-associated Death domain-dependent Pathways that Enhance Apoptosis Induced by -Irradiation, Journ. Biol. Chem., 275:12, Iss. Of March 24, 8610-8617, 2000.	

Examiner Signature		Date Considered	2/3/03
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		C m p l t i f K n w n	
		Application Number	----- 10/014,724
		Filing Date	November 7, 2001
		First Named Inventor	Michael N. Gould
		Group Art Unit	11016
		Examiner Name	D. J. [Signature]
Sheet 2	of 3	Attorney Docket Number	960296.97711

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	12	LI, JIE-HUI et al., The Regulation of CD95 Ligand Expression and Function in CTL, American Association of Immunologists 3943-3949, 1998.	
	13	MICHEAU, OLIVIER et al., Sensitization of Cancer Cells Treated with Cytotoxic Drugs to Fas-Mediated Cytotoxicity, J. Nat. Cancer Inst. 89:11, June 4, 1997.	
	14	MIZUTANI, YUICHI et al., Doxorubicin Sensitizes Human Bladder Carcinoma Cells to Fas-Mediated Cytotoxicity, Cancer 79:6, 1180-1189, March 15, 1997.	
	15	MUELLER, MARTINA et al., p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs, J. Exp. Med. 188:11, Dec. 7, 1998, 2033-2045.	
	16	NAGATA, SHIGEKAZU, Fas Ligand-Induced Apoptosis, Annu. Rev. Genet. 1999, 33:29-55.	
	17	O'CONNOR, LIAM et al., CD95 (Fas/APO-1) and p53 Signal Apoptosis Independently in Diverse Cell Types, Cancer Res. 60, 1217-1220, March 1, 2000.	
	18	PINKOSKI, M.J. and GREEN, D.R., Fas Ligand, Death Gene, Cell Death and Differentiation (1999) 6, 1174-1181.	
	19	ROKHLIN, OSKAR W., et al., Fas-Mediated Apoptosis in Human Prostatic Carcinoma Cell Lines Occurs Via Activation of Caspase-8 and Caspase-7, Cancer Research 58, 5870-5875, Dec. 15, 1998.	
	20	ROTH, W. et al., Taxol-Mediated Augmentation of CD95 Ligand-Induced Apoptosis of Human Malignant Glioma Cells: Association with bcl-2 Phosphorylation but Neither Activation of p53 nor G ₂ /M Cell Cycle Arrest, British J. of Cancer (1998) 77(3):404-411.	
	21	ROTH, WILFRIED et al., Interferon- γ Enhances CD95L-Induced Apoptosis of Human Malignant Glioma Cells, J. of Neuroimmun. 87 (1998) 121-129.	
	[Signature]	22	WELLER, MICHAEL, CD95 Ligand: Lethal Weapon Against Malignant Glioma? Brain Path. 8:285-293 (1998).

Examiner Signature	[Signature]	Date Considered	2/3/02
--------------------	-------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[Footer]

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <h2 style="margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="margin: 0;">(use as many sheets as necessary)</p>		C m p l e t e i f K n o w n			
		Application Number	----- 10/014724		
		Filing Date	November 7, 2001		
		First Named Inventor	Michael N. Gould		
		Group Art Unit	1618		
		Examiner Name	D Jones		
Sheet	3	of	3	Attorney Docket Number	960296.97711

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	23	WU, XIU-XIAN, Enhancement of Fas-Mediated Apoptosis in Renal Cell Carcinoma Cells in Adriamycin, Cancer Res. 60, 2912-2918, June 1, 2000.	
[Signature]	24	YOUNT, GARRET L., Fas (APO-1/CD95) Signaling Pathway is Intact in Radioresistant Human Glioma Cells, Cancer Res., 59, 1362-1365, March 15, 1999.	
[Signature]	25	ZAGURY, DANIEL, Toward a New Generation of Vaccines: the Anti-Cytokine Therapeutic Vaccines, PNAS 98:14 8024-8029, July 3, 2001.	


Examiner Signature	[Signature]	Date Considered	2/3/03
--------------------	-------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[Footer]



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/014,724
Filing Date	November 7, 2001
First Named Inventor	Michael N. Gould
Group Art Unit	3736 / 6 / P.
Examiner Name	D. Stone
Attorney Docket Number	960296.97711

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

[illegible]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**